Core Insights - AIM ImmunoTech Inc. presented data from a Phase 2 clinical study on Ampligen for advanced recurrent ovarian cancer, showing promising results at the 40th Annual SITC Meeting [1][2] Study Results - The study involved 27 platinum-sensitive patients, with 24 evaluable for response; 5 achieved complete response and 7 had partial response, resulting in an Objective Response Rate (ORR) of 50% [2] - This ORR is significantly higher compared to previous studies, such as Keynote-100, which reported ORRs of 7.4% and 9.9% for pembrolizumab alone [2] Mechanism and Potential - AIM believes that Ampligen can act synergistically with checkpoint inhibitors, potentially benefiting patients who do not respond to these therapies alone [3] - The study's findings suggest that Ampligen may enhance traditional cancer treatments, improving immune responses and prolonging remission for patients with limited options [4] Intellectual Property - AIM holds several patents related to the use of Ampligen in combination with checkpoint inhibitors, with expiration dates ranging from 2039 to 2040 in various jurisdictions [5] Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for cancers, immune disorders, and viral diseases, with Ampligen as its lead investigational drug [7]